Unprecedented drug discovery insights created by Cardea’s BPU platform

SAN DIEGO, Jan. 10, 2023 /PRNewswire/ — Today, Cardea Bio, Inc. achieves an 8-year milestone as the first external partner to begin using the Biosignal Processing Unit (BPU) platform to advance drug discovery and generate new and coveted insights.

Principal Investigator at Bar-Ilan University, Dr. Nir Qvit shares: “It’s kind of a love story between Cardea and my research as I’ve already published five articles on the BPU platform. In my estimation, the BPU platform is a very important tool for drug discovery as it is fast, easy to use and does not require many reagents. For example, the JoVE paper we published in March 2022 compared a BPU assay to isothermal titration calorimetry (ITC), a common biophysical measurement system. It took one day to collect the data with the BPU compared to fourteen days to collect the data for ITC with significantly more protein required. This illustrates how the BPU should be an important part of the drug discovery toolbox and a technology that all pharmaceutical companies can benefit from.”

While a postdoc at Stanford University in the Mochly-Rosen Lab, Dr. Nir Qvit caught the attention of Cardea’s Chief Technological Officer, Brett Goldsmith, PhD, who initiated a collaboration. The partnership continued after Bar-Ilan University Dr. Qvit offered his own laboratory focusing on the chemistry and biology of protein-protein interactions for drug discovery in pharmacology.

When I found out that Dr. When Qvit needed proof in vitro that its peptides bind to specific proteins, I immediately thought we could solve this with our graphene field effect transistor – the BPU. After attending a conference in San Francisco in January 2015, I stopped by the lab in the afternoon before having to catch a flight back to San Diego three hours later. Nir and I sampled its biochemistry with the honest expectation that we would show something promising and work on refining the measurements over the next few weeks. Surprised by the great results of those very first experiments, I kept rescheduling my flight so we could take more measurements. And we ended up capturing all the measurements that filled the gap to what Nir was missing for its release this afternoon! So even though I got home almost a day later than planned, it was a breakthrough for us and totally worth it,” says Dr. Brett Goldsmith, CTO at Cardea Bio.

READ :  Study published in Endocrinology by Heritage College researchers finds disruption of the growth hormone receptor gene in adipose tissue results in increased lifespan in mice

My aha moment came after Dr. Goldsmith visited our lab and we had success on the first day of experimentation. In the end we had exactly the high-quality results that I couldn’t achieve with any other technology.” says dr Qvit and continues: “Initially, we used the BPU platform to view binding interactions between known proteins and peptides that we designed and synthesized. Today we are also conducting competitive studies to see if our peptides can inhibit protein-protein interactions. I can’t wait to further develop the system to perform cell-based assays. With Cardea, I believe the possibilities to solve some of the biggest problems in drug discovery are realizable.

“When I got my own lab at Bar-Ilan University in 2017, I was immediately given the Agile R100 device with one BPU, which was only recently upgraded to the new Gateway Reader, which runs experiments on eight different BPUs at the same time. I was impressed, how quickly Cardea responded to our needs and how they in turn continuously improved their platform with a rapidly expanding range of features – improved software interfaces, automated analytics and the high quality and consistency of BPU performance.” closes dr Nir Qvit from Bar-Ilan University.

Examples of Nit Qvit releases highlighting Cardea’s BPU platform

About the Nir Qvit Lab in Bar-Ilan

Protein-protein interactions represent a significant fraction of functionally relevant biological interactions, and therefore the manipulation of these interactions is an important therapeutic strategy. The main focus of the Qvit laboratory is the identification of molecular modulators of the protein-protein interaction using bioinformatic analysis, peptide and protein chemistry and system-wide biological assays. The goal of the laboratory is to develop compounds capable of modulating protein complexes, which will allow a better understanding of the role of specific protein-protein interactions in cells and will be a starting point for the development of therapeutic compounds. Learn more at https://medicine.biu.ac.il/en/QvitNir

READ :  Salk Institute's Christina Towers recognized

About Cardea Bio

Cardea Bio is the world’s only mass producer of a biocompatible semiconductor, the BPU (Biosignal Processing Unit) platform. The BPU is the first and only graphene semiconductor capable of translating real-time streams of biological multiomics signals into digital information. By the BPUPlatform, Cardea’s long-term vision is to democratize access to the biosignals and insights that power the most advanced technology on our planet: nature and biology. The internet of biology is thus possible.

Cardea’s fast-growing IP portfolio now includes 33 broad-based issued patents and an additional 34 patents pending, solidifying Cardea’s market-leading position in the graphene biosensor industry, into which they bring the BPU (Biosignal Processing Unit) platform for marketing.

Cardea is headquartered in San Diego with additional operations in Los Angeles. Cardea is a 100% US designed and built biocompatible semiconductor graphene biosensor platform for applications in a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring and animal health.

Contact Cardea
Lasse Görlitz, Vice President Communications
US Phone: +1 858 319 7135
EU phone: +45 2758 2601
[email protected]


View original content to download multimedia: https://www.prnewswire.com/news-releases/previously-unachievable-drug-discovery-insights-created-by-cardeas-bpu-platform-301717809.html

SOURCE Cardea Bio

Leave a Reply

Your email address will not be published. Required fields are marked *